Starting and taking HUMIRA

 

Taking Humira

Here’s what you need to know about taking HUMIRA, including the support that’s available to stay on track

AbbVie Care

If you’re taking HUMIRA, you can join AbbVie Care – the personalised support programme that complements the care you receive from your specialist or clinic nurse

More

 

HUMIRA pen instructions

Instructions for using the HUMIRA single use pen

 NZ-IMM-0046

See step-by-step instructions

 

HUMIRA syringe instructions

Instructions for using the HUMIRA syringe

 NZ-IMM-0047

See step-by-step instructions

 

Storing and travelling with HUMIRA

Here’s how to store your HUMIRA properly and what to do when you’re travelling

More

 
Considering HUMIRA

Safety Information

Important safety information to know about HUMIRA

More

 

 

*AbbVie medications and programmes are designed to support patients on their health journey

NZ-HUM-0192. TAPS PP2498. August 2018.

This site is intended for a New Zealand audience.

Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use, pre-filled syringe (containing 20mg adalimumab) or single-use pen (containing 20mg or 40mg adalimumab). It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, chronic plaque psoriasis, ulcerative colitis, Crohn’s disease, non-infectious intermediate, posterior or pan-uveitis in adults, chronic non-infectious anterior uveitis in children >2, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).

HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available here: HUMIRA PEN CMI or HUMIRA Pre-filled Syringe CMI or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

HUMIRA is a fully funded medicine under Special Authority for most indications- normal pharmacy prescription charges apply. HUMIRA is not funded for enthesitis-related arthritis, non-radiographic axial spondyloarthritis, ulcerative colitis, uveitis and hidradenitis suppurativa – a pharmacy charge will apply. Normal doctor’s charges apply.

AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz | Medsafe HUMIRA Data Sheet

AbbVie Limited, 6th floor, 156-158 Victoria street, Wellington, 6011, New Zealand 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.

NZ-HUM-0181 TAPS PP2498 Last updated: August 2018. Copyright © AbbVie Limited.